Royal Bank of Canada reduced its position in shares of Cambrex Corporation (NYSE:CBM) by 25.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,065 shares of the biotechnology company’s stock after selling 1,415 shares during the period. Royal Bank of Canada’s holdings in Cambrex Corporation were worth $242,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in shares of Cambrex Corporation by 0.5% during the second quarter. BlackRock Inc. now owns 4,023,607 shares of the biotechnology company’s stock valued at $240,409,000 after acquiring an additional 20,652 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Cambrex Corporation by 0.9% during the second quarter. Dimensional Fund Advisors LP now owns 1,330,254 shares of the biotechnology company’s stock valued at $79,483,000 after acquiring an additional 11,762 shares during the last quarter. Congress Asset Management Co. MA increased its position in shares of Cambrex Corporation by 8.7% during the second quarter. Congress Asset Management Co. MA now owns 1,297,023 shares of the biotechnology company’s stock valued at $77,497,000 after acquiring an additional 103,900 shares during the last quarter. FMR LLC increased its position in shares of Cambrex Corporation by 19.1% during the second quarter. FMR LLC now owns 1,070,645 shares of the biotechnology company’s stock valued at $63,971,000 after acquiring an additional 171,559 shares during the last quarter. Finally, State Street Corp increased its position in shares of Cambrex Corporation by 7.6% during the first quarter. State Street Corp now owns 742,151 shares of the biotechnology company’s stock valued at $40,858,000 after acquiring an additional 52,638 shares during the last quarter.

A number of equities research analysts have weighed in on the stock. BidaskClub cut shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Saturday, August 12th. ValuEngine upgraded shares of Cambrex Corporation from a “hold” rating to a “buy” rating in a research report on Tuesday, August 22nd. Finally, Craig Hallum reissued a “buy” rating and issued a $60.00 price objective (down previously from $70.00) on shares of Cambrex Corporation in a research note on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $62.33.

Cambrex Corporation (NYSE:CBM) opened at $49.55 on Wednesday. Cambrex Corporation has a 12 month low of $42.55 and a 12 month high of $62.95. The company has a market cap of $1,576.60, a P/E ratio of 15.17, a PEG ratio of 1.08 and a beta of 2.26.

Cambrex Corporation (NYSE:CBM) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported $0.55 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.47 by $0.08. Cambrex Corporation had a net margin of 18.79% and a return on equity of 23.42%. The business had revenue of $112.60 million during the quarter, compared to analyst estimates of $108.44 million. During the same quarter last year, the firm posted $0.47 earnings per share. The business’s revenue for the quarter was up 13.4% compared to the same quarter last year. analysts anticipate that Cambrex Corporation will post 2.97 earnings per share for the current fiscal year.

In other news, CEO Steven M. Klosk sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $54.96, for a total value of $219,840.00. Following the completion of the transaction, the chief executive officer now owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $51.53, for a total transaction of $618,360.00. Following the completion of the transaction, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at approximately $4,912,251.84. The disclosure for this sale can be found here. Company insiders own 2.48% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Cambrex Corporation (CBM) Position Cut by Royal Bank of Canada” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/22/cambrex-corporation-cbm-position-cut-by-royal-bank-of-canada.html.

About Cambrex Corporation

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.